| Literature DB >> 33129241 |
Zohreh Hojati1, Farzaneh Omidi2, Moein Dehbashi1, Bahram Mohammad Soltani2.
Abstract
Entities:
Keywords: Alzheimer’s disease; Circulating microRNAs; Serum
Mesh:
Substances:
Year: 2020 PMID: 33129241 PMCID: PMC7748118 DOI: 10.29252/ibj.25.1.62
Source DB: PubMed Journal: Iran Biomed J ISSN: 1028-852X
Fig. 1The fold change graphs of hsa-miR-494-3p and hsa-miR-661. (A) The hsa-miR-494-3p was upregulated in AD patients as 0.34 fold change compared with the healthy controls (p = 0.86); (B) the hsa-miR-661 was downregulated in AD patients as three fold change compared with the healthy controls (p = 0.01); (C) ROC curves were drawn and AUC was calculated to evaluate and compare the diagnostic and prognostic potential of serum hsa-miR-661 in AD patients versus healthy controls. The calculations showed AUC = 75%, standard error = 0.08, and p value = 0.01; thus, hsa-miR-661 possessed the potential to be as a biomarker
Fig. 2The crossroad of metabolism, protein homeostasis, and cellular response to the stress pathway and ageing